Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia

Keyphrases

• Methotrexate 100%
• Childhood Acute Lymphoblastic Leukemia 100%
• Treatment Outcome 100%
• Methotrexate Resistance 100%
• Acute Lymphoblastic Leukemia 81%
• Leukemia Patients 45%
• Leukemic Cells 18%
• Metabolism 18%
• Leukemia Therapy 18%
• TEL-AML1 18%
• Methotrexate Polyglutamates 18%
• Reduced Folate Carrier 18%
• Clinically Significant 9%
• Molecular Mechanism 9%
• Treatment Response 9%
• Pediatric Acute Lymphoblastic Leukemia 9%
• Clinical Characteristics 9%
• Event-free Survival 9%
• Clinical Data 9%
• Novel Treatments 9%
• Tumor Cells 9%
• Cell Death 9%
• DNA Replication 9%
• Chemotherapy Regimen 9%
• High Accumulation 9%
• MRNA Expression 9%
• Delayed Diagnosis 9%
• Drug Resistance 9%
• Combination Chemotherapy 9%
• Patient Identification 9%
• Cytotoxic Agents 9%
• Chemoresistance 9%
• Clinical Differences 9%
• Long-term Clinical Outcome 9%
• Inhibition Assay 9%
• Concentration of Measure 9%
• Resistance Trends 9%
• Low Accumulation 9%
• Polyglutamate 9%
• Curative Effect 9%
• Working Diagnosis 9%
• Inpatient Treatment 9%
• Hyperdiploid 9%
• Outcome Characteristics 9%
• De Novo nucleotide Biosynthesis 9%

Biochemistry, Genetics and Molecular Biology

• Methotrexate 100%
• Metabolic Pathway 10%
• Drug Resistance 10%
• Folic Acid 10%
• Cell Death 5%
• Event Free Survival 5%
• Enzyme 5%
• DNA Synthesis 5%
• Nucleotide Metabolism 5%
• Messenger RNA 5%
• Combination Chemotherapy 5%
• Pediatrics 5%
• Molecular Mechanism 5%

Immunology and Microbiology

• Methotrexate 100%
• Drug Resistance 10%
• Tumor Cell 5%
• Cell Death 5%
• Event Free Survival 5%
• DNA Synthesis 5%
• Nucleotide Metabolism 5%
• In Vitro 5%